KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells.
Animals
Brain Neoplasms
/ genetics
Cell Line, Tumor
Cytokines
/ biosynthesis
Disease Progression
ErbB Receptors
/ immunology
Female
Glioblastoma
/ genetics
HEK293 Cells
Humans
Killer Cells, Natural
/ immunology
Mice
Mice, Inbred NOD
Mice, SCID
Random Allocation
Receptors, Chimeric Antigen
/ genetics
Xenograft Model Antitumor Assays
Chimeric antigen receptor
epidermal growth factor receptor variant III
glioblastoma
natural killer cells
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
30
04
2020
revised:
14
05
2020
accepted:
15
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
17
7
2020
Statut:
ppublish
Résumé
We previously established a novel type of epidermal growth factor receptor variant III (EGFRvIII)-specific chimeric antigen receptor (CAR)-expressing natural killer (NK) cell line, designated EvCAR-KHYG-1, which inhibited the growth of glioblastoma (GBM) cells in vitro via apoptosis. We investigated the cytokine-producing effect of EvCAR-KHYG-1 cells on GBM-like cell lines and their antitumour effect using in vivo xenograft assays. EvCAR-KHYG-1 cells produced interleukin-2, interferon-γ, and tumour necrosis factor-α on EGFRvIII-expressing U87MG cells. In vivo xenograft assays showed that EvCAR-KHYG-1 cells did not reduce the volume of subcutaneous tumours derived from EGFRvIII-expressing U87MG cells but did reduce tumour cell occupancy. EvCAR-KHYG-1 cells led to expression of cellular immunity-related cytokines on EGFRvIII-expressing U87MG in vitro but did not inhibit tumour progression due to the induction of a pseudo progression-like pathological feature. Future studies investigating the effect of different conditions in vivo are required to study the inhibition of tumour progression in GBM.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
We previously established a novel type of epidermal growth factor receptor variant III (EGFRvIII)-specific chimeric antigen receptor (CAR)-expressing natural killer (NK) cell line, designated EvCAR-KHYG-1, which inhibited the growth of glioblastoma (GBM) cells in vitro via apoptosis.
MATERIALS AND METHODS
METHODS
We investigated the cytokine-producing effect of EvCAR-KHYG-1 cells on GBM-like cell lines and their antitumour effect using in vivo xenograft assays.
RESULTS
RESULTS
EvCAR-KHYG-1 cells produced interleukin-2, interferon-γ, and tumour necrosis factor-α on EGFRvIII-expressing U87MG cells. In vivo xenograft assays showed that EvCAR-KHYG-1 cells did not reduce the volume of subcutaneous tumours derived from EGFRvIII-expressing U87MG cells but did reduce tumour cell occupancy.
CONCLUSION
CONCLUSIONS
EvCAR-KHYG-1 cells led to expression of cellular immunity-related cytokines on EGFRvIII-expressing U87MG in vitro but did not inhibit tumour progression due to the induction of a pseudo progression-like pathological feature. Future studies investigating the effect of different conditions in vivo are required to study the inhibition of tumour progression in GBM.
Identifiants
pubmed: 32487617
pii: 40/6/3231
doi: 10.21873/anticanres.14304
doi:
Substances chimiques
Cytokines
0
Receptors, Chimeric Antigen
0
epidermal growth factor receptor VIII
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3231-3237Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.